Venous Thromboembolism
Conference Coverage
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
Conference Coverage
Switching to riociguat effective for some patients with PAH not at treatment goal
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
Conference Coverage
Selexipag has no effect on daily activity in PAH patients
After 24 months of daily tracking, there was no benefit to increased daily activity for patients taking this drug.
Conference Coverage
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides
Conference Coverage
TNF inhibitors cut odds of VTE in RA patients
Rather than increase risk for venous thromboembolism events, TNF inhibitors cut risk by nearly half, and other newer biologics lowered risk by...
From the Journals
Renal function data improve risk stratification in patients with PAH
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Smokers with PE have higher rate of hospital readmission
NEW ORLEANS – The rate of readmission within 30 days was significantly higher among PE patients with tobacco...
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.